These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 16507550

  • 1. Serum chemical biomarkers of cardiac injury for nonclinical safety testing.
    Walker DB.
    Toxicol Pathol; 2006; 34(1):94-104. PubMed ID: 16507550
    [Abstract] [Full Text] [Related]

  • 2. Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity.
    O'Brien PJ.
    Toxicology; 2008 Mar 20; 245(3):206-18. PubMed ID: 18249481
    [Abstract] [Full Text] [Related]

  • 3. Preclinical assessment of cardiac toxicity.
    Kettenhofen R, Bohlen H.
    Drug Discov Today; 2008 Aug 20; 13(15-16):702-7. PubMed ID: 18602016
    [Abstract] [Full Text] [Related]

  • 4. Troponin as a biomarker of cardiac toxicity: past, present, and future.
    Reagan WJ.
    Toxicol Pathol; 2010 Dec 20; 38(7):1134-7. PubMed ID: 20884820
    [Abstract] [Full Text] [Related]

  • 5. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials.
    Food Chem Toxicol; 2008 Mar 20; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [Abstract] [Full Text] [Related]

  • 6. Metabolites in safety testing.
    Robison TW, Jacobs A.
    Bioanalysis; 2009 Oct 20; 1(7):1193-200. PubMed ID: 21083045
    [Abstract] [Full Text] [Related]

  • 7. Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative.
    Piccini JP, Whellan DJ, Berridge BR, Finkle JK, Pettit SD, Stockbridge N, Valentin JP, Vargas HM, Krucoff MW, CSRC/HESI Writing Group.
    Am Heart J; 2009 Sep 20; 158(3):317-26. PubMed ID: 19699852
    [Abstract] [Full Text] [Related]

  • 8. Blood cardiac troponin in toxic myocardial injury: archetype of a translational safety biomarker.
    O'Brien PJ.
    Expert Rev Mol Diagn; 2006 Sep 20; 6(5):685-702. PubMed ID: 17009904
    [Abstract] [Full Text] [Related]

  • 9. Clinical biomarkers of cardiac injury: cardiac troponins and natriuretic peptides.
    Apple FS.
    Toxicol Pathol; 2006 Sep 20; 34(1):91-3. PubMed ID: 16507549
    [Abstract] [Full Text] [Related]

  • 10. Glial fibrillary acidic protein and related glial proteins as biomarkers of neurotoxicity.
    O'Callaghan JP, Sriram K.
    Expert Opin Drug Saf; 2005 May 20; 4(3):433-42. PubMed ID: 15934851
    [Abstract] [Full Text] [Related]

  • 11. Overview of the nonclinical quality and toxicology testing for recombinant biopharmaceuticals produced in mammalian cells.
    Lebrec H, Narayanan P, Nims R.
    J Appl Toxicol; 2010 Jul 20; 30(5):387-96. PubMed ID: 20589744
    [Abstract] [Full Text] [Related]

  • 12. Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring.
    Muller PY, Dieterle F.
    Expert Opin Drug Metab Toxicol; 2009 Sep 20; 5(9):1023-38. PubMed ID: 19611406
    [Abstract] [Full Text] [Related]

  • 13. A search to predict potential for drug-induced cardiovascular toxicity.
    Hamlin RL.
    Toxicol Pathol; 2006 Sep 20; 34(1):75-80. PubMed ID: 16507547
    [Abstract] [Full Text] [Related]

  • 14. Alternative methods to safety studies in experimental animals: role in the risk assessment of chemicals under the new European Chemicals Legislation (REACH).
    Lilienblum W, Dekant W, Foth H, Gebel T, Hengstler JG, Kahl R, Kramer PJ, Schweinfurth H, Wollin KM.
    Arch Toxicol; 2008 Apr 20; 82(4):211-36. PubMed ID: 18322675
    [Abstract] [Full Text] [Related]

  • 15. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies.
    Ponce R, Abad L, Amaravadi L, Gelzleichter T, Gore E, Green J, Gupta S, Herzyk D, Hurst C, Ivens IA, Kawabata T, Maier C, Mounho B, Rup B, Shankar G, Smith H, Thomas P, Wierda D.
    Regul Toxicol Pharmacol; 2009 Jul 20; 54(2):164-82. PubMed ID: 19345250
    [Abstract] [Full Text] [Related]

  • 16. Optimising the design of preliminary toxicity studies for pharmaceutical safety testing in the dog.
    Smith D, Combes R, Depelchin O, Jacobsen SD, Hack R, Luft J, Lammens L, von Landenberg F, Phillips B, Pfister R, Rabemampianina Y, Sparrow S, Stark C, Stephan-Gueldner M.
    Regul Toxicol Pharmacol; 2005 Mar 20; 41(2):95-101. PubMed ID: 15698532
    [Abstract] [Full Text] [Related]

  • 17. Novel biomarkers of acute kidney toxicity.
    Goodsaid FM, Blank M, Dieterle F, Harlow P, Hausner E, Sistare F, Thompson A, Vonderscher J.
    Clin Pharmacol Ther; 2009 Nov 20; 86(5):490-6. PubMed ID: 19710639
    [Abstract] [Full Text] [Related]

  • 18. Cardiac troponin I is a sensitive, specific biomarker of cardiac injury in laboratory animals.
    O'Brien PJ, Smith DE, Knechtel TJ, Marchak MA, Pruimboom-Brees I, Brees DJ, Spratt DP, Archer FJ, Butler P, Potter AN, Provost JP, Richard J, Snyder PA, Reagan WJ.
    Lab Anim; 2006 Apr 20; 40(2):153-71. PubMed ID: 16600075
    [Abstract] [Full Text] [Related]

  • 19. Nonclinical development of biopharmaceuticals.
    Baumann A.
    Drug Discov Today; 2009 Dec 20; 14(23-24):1112-22. PubMed ID: 19853058
    [Abstract] [Full Text] [Related]

  • 20. Juvenile animal toxicity study designs to support pediatric drug development.
    Cappon GD, Bailey GP, Buschmann J, Feuston MH, Fisher JE, Hew KW, Hoberman AM, Ooshima Y, Stump DG, Hurtt ME.
    Birth Defects Res B Dev Reprod Toxicol; 2009 Dec 20; 86(6):463-9. PubMed ID: 20025047
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.